Key Points
- Insider confidence increased: Paul Glavine bought 100,000 Cybin shares for approximately $1.18 million, raising his direct ownership to 4.17 million shares. He had also purchased 90,000 shares days earlier.
- Cybin’s stock has risen sharply but remains volatile: Shares opened at $12.84, compared with a 52-week range of $3.76 to $14.35, despite trading down 6.1% and the company remaining unprofitable.
- Analyst sentiment is broadly positive, but risks remain: Five analysts rate Cybin a “Buy,” with a consensus price target of $48.60, while the company recently missed quarterly EPS expectations and is projected to post a full-year loss.
Cybin Inc. (NASDAQ:HELP - Get Free Report) insider Paul Glavine purchased 100,000 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was acquired at an average cost of $11.78 per share, with a total value of $1,178,000.00. Following the completion of the acquisition, the insider directly owned 4,171,252 shares of the company's stock, valued at $49,137,348.56. This represents a 2.46% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Paul Glavine also recently made the following trade(s):
- On Monday, August 31st, Paul Glavine acquired 90,000 shares of Cybin stock. The shares were bought at an average cost of $11.59 per share, for a total transaction of $1,043,100.00.
Cybin Trading Down 6.1%
Shares of NASDAQ:HELP opened at $12.84 on Friday. The company has a market capitalization of $970.83 million, a PE ratio of -4.25 and a beta of 0.63. Cybin Inc. has a twelve month low of $3.76 and a twelve month high of $14.35. The firm has a 50 day simple moving average of $9.84 and a 200-day simple moving average of $6.85.
Cybin (NASDAQ:HELP - Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.11). As a group, equities research analysts predict that Cybin Inc. will post -2.95 EPS for the current fiscal year.
Institutional Trading of Cybin
A number of large investors have recently bought and sold shares of HELP. Osaic Holdings Inc. grew its position in Cybin by 46.7% during the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company's stock worth $63,000 after purchasing an additional 2,400 shares during the last quarter. AXQ Capital LP acquired a new position in Cybin in the second quarter valued at $75,000. Bank of America Corp DE raised its holdings in shares of Cybin by 66.8% in the second quarter. Bank of America Corp DE now owns 29,443 shares of the company's stock valued at $247,000 after buying an additional 11,790 shares during the last quarter. Pale Fire Capital SE purchased a new stake in shares of Cybin in the second quarter valued at about $1,015,000. Finally, Millennium Management LLC raised its holdings in shares of Cybin by 1,388.5% in the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company's stock valued at $8,414,000 after buying an additional 959,448 shares during the last quarter. Institutional investors and hedge funds own 17.94% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have issued reports on HELP. Wells Fargo & Company started coverage on Cybin in a report on Monday, July 27th. They set an "overweight" rating and a $16.00 price objective on the stock. TD Cowen boosted their target price on Cybin from $8.00 to $62.00 and gave the company a "buy" rating in a report on Thursday, August 20th. Finally, Wall Street Zen raised Cybin from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 29th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Cybin has an average rating of "Buy" and a consensus target price of $48.60.
Read Our Latest Report on Cybin
Cybin News Roundup
Here are the key news stories impacting Cybin this week:
- Positive Sentiment: Insider buying was notable: Paul Glavine purchased 100,000 shares for approximately $1.18 million, while Eric H. L. So bought 100,000 shares for about $1.21 million. Both increased their direct holdings by more than 2%. Glavine and So also reported earlier purchases of 90,000 and 95,000 shares, respectively, suggesting continued insider confidence. SEC insider purchase filing
- Positive Sentiment: Helus Pharma, Cybin’s commercial name, is scheduled to present at the H.C. Wainwright and Morgan Stanley healthcare conferences. Investor attention may increase because CEO Michael Halstead is expected to discuss the company’s mental-health pipeline, including Phase 3 HLP003 for major depressive disorder and Phase 2 HLP004 for generalized anxiety disorder. Morgan Stanley conference announcement
- Neutral Sentiment: The reported short-interest update shows zero shares short and a zero-day days-to-cover ratio, but it also reports an impossible “NaN” percentage change from the prior period. The data therefore offers little reliable insight into current trading pressure.
- Negative Sentiment: Cybin remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.91 per share exceeded the expected $0.80 loss, and analysts anticipate a full-year loss of approximately $2.95 per share. With no new trial results or regulatory approval announced, investors may be taking profits after the stock’s sharp recent rise and reacting to ongoing development and financing risks.
About Cybin
(
Get Free Report)
Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.
The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
